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 KAJIAN ANTIHIPERGLISEMIK DAN KETOKSIKAN EKSTRAK AKUES 
– ETANOL GYNURA PROCUMBENS  
ABSTRAK  
Daun Gynura procumbens (sambung nyawa) telah digunakan dalam 
perubatan tradisional Melayu untuk merawat diabetes. Adalah difahami bahawa daun 
mengandungi banyak sebatian dan hanya satu atau sebahagian daripadanya 
mempunyai aktiviti antidiabetik. Oleh itu, tujuan kajian ini adalah untuk mengekstrak 
daun menggunakan pelarut berbeza kepolaran, campuran nisbah yang berbeza antara 
etanol-air bagi memilih ekstrak yang mengandungi sebatian dengan aktiviti 
antidiabetik tertinggi dan menjalankan ujian ketoksikan akut dan subkronik terhadap 
ekstrak yang mempunyai aktiviti tertinggi. Aktiviti antidiabetik ekstrak-ekstrak 
dibanding berdasarkan kebolehan ekstrak-ekstrak menurunkan paras glukosa darah 
tikus normal dan tikus diabetik aruhan streptozotosin. Serbuk daun tumbuhan yang 
dikeringkan diekstrak menggunakan etanol  0, 25, 50, 75 dan 95% dan dipekatkan 
menggunakan penyejat berputar, masing  masing. Ekstrak  ekstrak etanol 0, 25, 50, 
75 dan 95% menurunkan secara signifikan (p<0.005) paras glukosa darah tikus 
diabetik aruhan streptozotosin pada jam ke – 3 dan 5 selepas pemberian secara oral 1 
g/kg ekstrak. Ekstrak 25% etanol menunjukkan aktiviti antidiabetik tertinggi dan 
sama seperti metformin menurunkan secara signifikan (p<0.005) paras glukosa darah 
pada jam ke -2, 3, 5 dan 7 selepas pemberian. Bagi analisis fitokimia, ekstrak etanol 
75% mengandungi kandungan flavanoid tertinggi, sementara ekstrak air 
menunjukkan nilai terendah. Tambahan pula, fraksi n-butanol daripada ekstrak etanol 
 
XXI 
 
25% menunjukkan nilai tertinggi kandungan flavonoid dan fenolik. Kandungan 
fenolik tertinggi didapati dalam ekstrak etanol 50%. Kandungan asid klorogenik 
menunjukkan paras tertinggi dalam ekstrak etanol 70%. Ekstrak etanol 25% disisih 
menggunakan pelarut berbeza kepolaran seperti heksana, etil asetat, klorofom, n-
butanol dan air. Aktiviti antihiperglisemik bagi setiap fraksi kemudian dinilai melalui 
pemberian akut dan berulang ekstrak etanol 25% G. procumbens dan fraksi – fraksi 
pada dos 500, 1000,  2000 mg/kg  selama 14 hari dan kesan ekstrak dan fraksi – 
fraksi terhadap enzim α- glukosidase and α- amilase (in vivo dan in vitro) juga dikaji. 
Keputusan menunjukkan fraksi n-butanol mempamerkan kesan antihyperglisemic 
yang lebih kuat berbanding fraksi etil asetat dan akues. Hasil kajian menunjukkan 
bahawa pecahan butanol mempunyai kesan tertinggi pembetulan terhadap 
hiperglisemia setelah makan siang selepas pemberian kanji dan sukrosa dalam tikus 
normal dan diabetik oleh perencatan aktiviti α-glucosidase dan α-amilase. Penemuan 
ini menunjukkan bahawa fraksi n-butanol mampu mempamerkan kesan penurunan 
glukosa yang signifikan pada dos 1000 mg/kg sama seperti metformin 500mg/kg 
disebabkan kehadiran komponen aktif polifenolik seperti asid klorogenik, rutin dan 
kemferol -3-O-rutinosid. Tambaban pula, hal ini mencadangkan bahawa fraksi n – 
butanol mempunyai kesan antihiperglisemik yang lebih baik berbanding fraksi etanol 
25% G. procumbens. Akhir sekali, kajian ketoksikan akut dan subkronik 
menunjukkan bahawa ekstrak etanol 25% G. procumbens boleh dianggap tidak 
mempunyai sebarang risiko toksik. 
Kata kunci: Gynura procumbens, aktiviti antidiabetik, antihiperglisemik, perencat α- 
glukosidase, ketoksikan akut dan subkronik.  
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ANTIHYPERGLYCEMIC AND TOXICOLOGICAL  STUDIES  OF 
ETHANOLIC– AQUEOUS  EXTRACTS  OF GYNURA PROCUMBENS     
ABTRACT 
Leaves of Gynura procumbens (sambung nyawa) have been used in Malay 
traditional medicine among others to treat diabetes. It is understood that the leaves 
contain many compounds and only one or a few of these compounds possess the 
antidiabetic activity. Therefore, the aim of this study was to extract the leaves using 
solvents of different polarity, mixtures of the different ratio of ethanol-water to select 
the extract that contains compound(s) with the strongest antidiabetic activity and  to 
carry out acute and subchronic toxicity tests of the  extract with better activity. The 
antidiabetic activity of the extracts was compared based on their ability to lower 
down the blood-glucose level of normal rats and streptozotocin-induced diabetic rats. 
Dried powdered leaves of the plant were extracted with 0, 25, 50, 75 and 95% 
ethanol and concentrated using rotary evaporator respectively. The 0, 25, 50, 75 and 
95% ethanol extracts respectively significantly reduced (p<0.005) blood-glucose 
level of streptozotocin induced diabetic rats  at 3
rd
 and 5
th
 hours after oral 
administration of 1000  mg/kg of the extracts. The 25% ethanol extract showed the 
strongest antidiabetic activity and similar to metformin significantly reduced 
(p<0.005) blood-glucose level at  the 2
nd
, 3
rd
, 5
th
 and 7
th
 hours after administration. 
In the phytochemical analysis the 75% ethanolic extract contained  the highest  
flavonoids  content,  while the water extract  showed  the lowest value. In addition, 
the n-butanol fraction from 25% ethanolic extract  represented  the highest value of 
flavonoids and phenolics  contents. The highest phenolics content was found in 50 % 
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ethanolic extract, although chlorogenic acid content showed the highest level in 75% 
ethanolic extract. The 25% ethanolic extract was fractionated with solvents  of 
differing degree of  polarity such as hexane, ethyl acetate, chloroform, n-butanol and 
water. The antihyperglycemic activity  each  fraction was then assessed by acute, 
repeating administration  of  25% ethanolic extract of  G. procumbens and fractions at 
doses  of 500, 1000 and   2000 mg/kg  respectively for 14 days  and  also, by 
investigating the effect of the extract and its fraction on  α-glucosidase and α-amylase 
enzymes  activities in vivo and in vitro.  It seems that butanol fraction possess the 
highest corrective effect on postprandial hyperglycemia after administration of starch 
and sucrose in the normal and diabetic rats by inhibition of the α-glucosidase and α-
amylase acivities. Furthermore, the results indicate that n-butanol fraction  exhibited  
a stronger antihyperglycemic  effect than the ethyl acetate and aqueous fractions.. 
These findings  showed  that the n-butanol fraction  could exert a significant  glucose  
lowering  effect at dose 1000 mg/kg  similar  to that  metformin 500 mg/kg  due to 
the presence of  polyphenolics  active constituents such as chlorogenic acid, rutin and 
kaempferol-3-O-rutinoside. In addition, it suggested that the n-butanol fraction had a 
better  antihyperglycemic and acumulative  effects than  the other   fractions of 25% 
ethanolic G. procumbens. Finally, the acute and subchronic toxicity study showed 
that the 25 % ethanolic extract of G. procumbens can be considered devoid of any 
toxic  risk. 
 
Keywords:       Gynura procumbents, antidiabetic activity, antihyperglycemic, α- 
glucosidase inhibitor, acute and subchronic toxicity 
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Chapter 1 
Introduction 
1.0. Diabetes Mellitus 
Diabetes mellitus is a metabolic disorder characterized by a loss of glucose 
homeostasis with disturbances of carbohydrate, fat and protein metabolism resulting 
from defects in insulin secretion, insulin action, or both (DeFronzo, 2004).
i
Without 
enough insulin, body tissues, in particular, the liver, muscle and adipose tissues fail 
to take and utilize glucose from the blood circulation. This results in elevated blood 
glucose levels, a condition known as hyperglycemia. If blood glucose levels remain 
high over a long period of time, this can result in long-term damage of organs such 
as the kidneys, eyes, nerves, heart and blood vessels. Complications in some of these 
organs can lead to death (Brownlee, 2001;
ii
Weiss and Sumpio, 2006). 
Currently, type II diabetes mellitus, the most common type of diabetes mellitus, is 
managed by a combination of diet, exercise, oral hypoglycemic drugs and sometimes 
insulin injections (Day and Bailey, 2006).
iii
 However, synthetic oral hypoglycemic drugs, 
which are currently the main form of treatment for type II diabetes mellitus have been 
shown to have undesirable side effects and high secondary failure rates (Alberti and 
Zimmet., 1998).  In addition, these drugs cannot be afforded by the majority of people 
living in rural communities of developing countries such as South Africa because of their 
high cost (Day and Bailey, 2006). These limitations, of currently available antidiabetic 
pharmacological agents have prompted researchers all over the world to investigate 
alternative antidiabetic remedies. In particular, consideration is given to plants and herbs 
used by traditional healers and herbalists as antidiabetic remedies with the hope of 
discovering new natural products that can be used or developed into safe, inexpensive and 
effective antidiabetic remedies. In this context, a number of medicinal plants and herbs 
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have been studied and validated for their hypoglycaemic potential using experimental 
animal models of diabetes (Kesari et al., 2005;
iv
Ruzaidi et al., 2005)
v
 as well clinical 
studies involving diabetic patients. (Jaouhari et al.,1999;
vi
 Herrera-Arellano et al., 2004;  
Jayawardena et al., 2005). In addition, bioactive compounds of most of these plants have 
been isolated and identified (Grover et al., 2002; Jayawardena et al., 2005). However, 
mechanisms of action whereby most of these plants and their products exert their blood 
glucose lowering effects on tissue or organs remain unknown. 
Gynura procumbens (Lour)  Merr,  a composite known locally in Malaysia as Sambung 
Nyawa, is an annual evergreen shrub that grows extensively in South East Asia, 
particularly in Indonesia, Malaysia, and Thailand, where it is traditionally used for 
treatment of eruptive fevers,  rash,  kidney disease,  migraines,  constipation, hypertension, 
diabetes mellitus, and cancer . Some of these traditional claims have been validated in 
scientific and pharmacological studies, including, anti-herpes simplex virus, anti-
inflammatory, and antihypertensive activities.  
G. procumbens has of recent received particular attention in the pharmacology of 
antidiabetic medicinal plants, probably because of its avowed empirical evidence and efficacy in 
the traditional management of diabetes. However, the scientific reports on the antidiabetic 
activity of this plant have been conflicting and inconsistent. For instance, Zhang and Tan (2000) 
had reported that 95%  ethanol extract  improved glucose  tolerance    in STZ induced diabetic 
rats, but not in normal rats. Its aqueous extract was also reported by these authors to exert 
significant antihyperglycemic action in STZ-induced diabetic rats. Later on, Akowuah et al 
(2009) on the contrary indicated its glucose lowering effect in normal rats. In a most recent study, 
the extract of G. procumbens  was reported to produce significant elevation in the fasting blood 
glucose levels of normal rats, but a decrease in diabetic rats. There is a basic need to stream line 
these reports, given the widespread traditional applications of use of G. procumbens.  Moreover, 
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these study designs are not targeted at natural product discovery or production of standardized 
herbal forms. Adequate research on medicinal plants beyond screening for biological activity 
should be conducted with the aim to systematically standardize and develop them into natural 
products or dosage forms which should effectively complement or supplement existing 
conventional measures. Consequently, the present investigation using ethnomedical drug 
discovery program, evaluated the antidiabetic activity of G. procumbens used in the traditional 
health system of the South East Asia, as an effective remedy and management for diabetes 
mellitus and other ailments. A systematic screening such as this is a fundamental requirement for 
natural product exploration and development of therapeutic agents from medicinal plants. 
1.1. The objectives of this study  
1-To evaluate the antihyperglycaemic activities of ethanolic-aqueous extract of G. procumbens 
(95%, 75%, 50%, 25% ethanolic and water extracts) on normal and STZ induced diabetic rats.  
2- To standardize the phytochemical constituents contained in the most potent antihyperglycemic 
extract. 
3- To fractionate the most active antihyperglycemic ethanolic-aqueous extract and investigate 
the antidiabetic activity of the fraction in the normal and STZ induced diabetic rats.  
4- To investigate the antidiabetic mode of action of the most bioactive extract and its fractions 
(ethyl acetate, n-butanol and aqueous) on inhibition of postprandial hyperglycaemia in  vitro 
and in vivo animal models by studying the effect of the extract and fractions on α-glucosidase  
and α-amylase enzymes activity. 
5- To evaluate the acute and subchronic toxicity of the most bioactive extract. 
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Chapter 2 
Literature Review 
 
2.0. Epidemiology  and Incidence of diabetes mellitus  
The growing seriousness of diabetes in the world can be based  on the increase in 
patients, especially in developing countries. According to WHO reports, there are more 
than 180 million people worldwide suffering from diabetes, and these numbers  are likely 
to double by 2030.  In 2005, an estimated 1.1 million people died from diabetes, with 
approximately 80% of these deaths occurring in poor and developing countries.  Almost 
half of these deaths was in people under the age 70 years with 55%  being women. The 
WHO estimates that diabetes related deaths will increase by more than 50% in the next 10 
years, if the disease is not given urgent attention. Most notably, diabetes deaths are 
projected to increase by over 80% in the upper-middle income between 2006 and 2015. 
Diabetes and its complications therefore pose significant economic and public health 
consequences for individuals, families, health system and countries (WHO, 2006). 
 
Diabetes mellitus is a serious diseases affecting both poor and rich countries and 
also affecting both male and female as well as across racial lines. Obesity and lifestyle 
related to socio–economic status and nutrition of the people are the important risk factors 
that can increase  the incidence of diabetes mellitus.  In the world’s  highly industrialized 
countries, the prevalence is very high owing to the lush lifestyle the people are leading 
(Amos et al., 1997).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
Diabetes mellitus is a growing health concern in Malaysia. The number of diabetic 
patients in Malaysia is increasing while complication rates and associated diseases among 
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diabetes are significantly high. Nowadays, low priority for a good eating habit and low 
awareness in health care represent the most problems in the people. Prevalence of diabetes 
mellitus in this country has also steadily increased over the years with an estimate of 
0.65% in 1960, to 2% in 1982. Diabetes screening in the year 2002 showed that 80,204 
cases were screened with 2,606 cases (65%) were normal, 14,271 (18%) cases were 
abnormal,  and 13,327 (17%) cases were borderline case. Data in 2002 showed that 6,288 
diabetes cases had their eye screened with undus cameras and the result showed that 4,150 
cases or 66% was normal whereas 2,138 cases or 34% had some form of retinopathy 
(Ooyub et al., 2004). Currently there are around 1.2 million diabetes in Malaysia, with 
98% of them diagnosed with diabetes mellitus type II. This means that there is 
approximately 8 diabetes in every 100 adults. The WHO has estimated that in 2030, 
Malaysia would have  a total number of 2.48 million people inflicted with diabetes  
compared  to 0.94 million in  2000 with an increase 164 %  (PDM, 2007). This increase 
can be attributed to many factors, including a stressful lifestyle as well as improper dietary 
habits. This is of economic concern as the disease requires life-long treatment and is also 
associated with high morbidity from the resulting complications. 
 
2.1. Classification of Diabetes Mellitus  
Diabetes mellitus is classified into three major disease syndromes. 
 Type I diabetes (previously known as insulin-dependent or childhood-onset) is 
characterized by a lack of insulin production. Type I diabetes is thought to result 
from an infectious or toxic environmental contingency in people whose immune 
systems are genetically predisposed to develop a vigorous autoimmune response 
against pancreatic β-cells antigen. There are many extrinsic factors that might 
affect β cells functioning, these factors include damage of these cells by certain 
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viruses  such as the mumps virus and coxsakie virus B4, by chemical agents or by 
destructive cytotoxins and antibodies release from sensitized immunocytes. The 
degree of the damage of β-cells in diabetes mellitus I can be lessened at the initial 
manifestation by treatment with immunosuppressive drugs such as cyclosporine or 
azathioprine are (Nolte and Karam, 2001). The most frequent symptoms of 
diabetes mellitus include excessive urine production (polyuria) thirst (polydipsia), 
constant hunger despite the patient having a voracious appetite (polyphagia), 
weight loss, coma, voracious change and fatigue (WHO, 2006). 
 Type II diabetes mellitus (called non- insulin dependent or maturity /adult-onset 
diabetes onset diabetes) results from the body‘s inability to use insulin, which results 
in its accumulation in the fat cells (WHO, 2006). It is the most common from of 
diabetes and is characterized by disorders of insulin action and insulin secretion, and 
either one can be the predominant feature (Alberti and Zimmet., 1998). Diabetes 
mellitus type II comprises 90 % of the cases of diabetes in people around the world 
and largely the result of excessive body weight and physical inactivity. Symptoms 
may be similar to those of diabetes mellitus type I but are often less marked. 
Diabetes mellitus type II is characterized by fasting and postprandial hyperglycemia. 
If left untreated hyperglycemia may cause long term microvascular and 
macrovascular complications, such as nephropathy, retinopathy and atherosclerosis. 
The pathogenesis in diabetes type II is that the pancreas produces insulin, but the 
body does not utilize the insulin correctly. This is primarily due to peripheral tissues 
insulin resistance where insulin receptor or other intermediates in the insulin 
signaling pathways within body cells are insensitive to insulin and consequently 
glucose does not enter the tissues leading to hyperglycemia or elevated blood-
glucose concentrations (Albright, 1997). Obesity, which generally results in 
 7 
 
impaired  insulin  action, is the common risk factor for this type of diabetes and most 
patients with diabetes type II are obese (Nolte and Karam, 2001) and will ultimately 
require multi antidiabetic agents to maintain  adequate glycemic control (Gerich, 
2001). There are many ways in treatment of diabetes type II patients such as 1- 
increase physical activity to reduce weight (consequently insulin resistance). 2- 
Reduce intake of dietary fat and adequate intake of complex carbohydrates and 
fiber, which improves insulin action and secretion through medical intervention, i.e. 
several commercial pharmaceutical that either enhances insulin action or secretion. 
The first treatment option is most beneficial as drug therapy may be associated with 
the long term underlying and undesired effects such as excessive weight loss (Jain 
and Saraf., 2008). 
    Table 2.1. Classification of  Diabetes Mellitus (Jain and Saraf., 2008). 
 
 Type III gestational diabetes, this type of diabetes occurs during pregnancy. 
During pregnancy the need for insulin appear to increase and gestational diabetes 
occurs at the late stages of pregnancy. This type of diabetes mellitus may goes 
away once the baby has been born but type II diabetes may develop later in life, in 
women who has gestational diabetes. 
Mode of classification Type I Diabetes Mellitus 
Type II Diabetes 
Mellitus 
Ages at onset 
Juvenile –onset (JOD) 
occurs predominantly in 
children and young adults 
Maturity Onset 
Diabetes (MOD) 
occurs predominantly 
in middle –aged or old 
people 
Insulin dependence 
Insulin dependent diabetes 
(IDDM). A patient reqires 
insulin therapy to prevent 
ketoacidosis 
Non insulin dependent 
diabetes (NIDDM) 
give insulin treatment  
for better control often 
advisable especially in 
younger patients. 
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2.1.1. Factors influencing the prevalence of diabetes mellitus   
There are many factors influence the prevalence of diabetes such as age, sex, obesity, 
lifestyle and gender.  
 
2.1.2.  Symptoms  and diagnosis of diabetes mellitus   
 Intense hunger and thirst. 
 Frequent urination. 
 Unusual weight loss.  
 Increased fatigue. 
 Itchy skin Slow healing of cuts and wounds.  
 Frequent infections. 
 Blurred vision. 
 Numbness or tingling, especially in your feet and hands. 
 Sexual dysfunction among men. 
2.2. Glucose metabolism  
 
2.2.1.  Digestion and absorption of carbohydrates  
Like any machine the body requires fuels to provide energy for it to function. The 
fuels the body needs come from the food we eat, which are made up of carbohydrates 
(sugars and starch), proteins and fats. These carbohydrates, proteins and fats are split apart 
by digestive enzyme into their basic building blocks glucose, amino acids and fatty acids 
respectively.There is a series of chemical reactions in the metabolic pathway which 
produces energy from glucose and this pathway is called the Krebs cycle that is coupled to 
the electron transfer chain present in all cells (Krall and Besar., 1989). 
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There are three stages (Fig 2.1) that must occur in order to generate energy from 
the food: 
 The first stage involves the breakdown of large molecules into smaller 
units, i.e. proteins hydrolyzed to their twenty kind of amino acids, 
polysaccharides are hydrolyzed to simple sugars (glucose and fructose)  
and fats hydrolyzed to fatty acids and glycerol by lipases enzymes. 
 The second stage involves the small units from the first stage are degraded 
into a few simple units that play a pivotal role in the metabolism. Here 
most of the sugars, amino acids and fatty acids are converted into acetyl 
CoA and small amount of adenosine triphosphate (ATP) is generated.   
 The third stage consists of citric acid cycle and oxidative phosphorylation, 
the final pathway in the oxidation of fuel molecules. Acetyl units are 
completely oxidized at this stage to CO2 and four pairs of electrons are 
transferred to nicotinamide adenine dinucleotide (NAD) and flavin 
adenine dinucleotide (FAD) for each acetyl group that is oxidized. ATP is 
then generated as electrons flow from the reduced form of these carriers to 
O2 in a process known as oxidative phosphorylation.  The bulk of ATP is 
generated in this stage (Stryer and Jeremy, 2007). 
 
2.2.2.  Hormones  Control of Carbohydrate Metabolism 
 
                    Hormones such as insulin and glucagon play an important role in regulation of 
glucose metabolism and maintain the hemostats in the body. The proper functions of the 
body are dependent on precise control of the glucose concentration in the blood. The 
normal fasting level of glucose in the blood is 3.8-5 mmol/l. If the concentration of 
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glucose in blood is too high (above 8 mml/l) a condition known as hyperglycemia results. 
Hyperglycemia may temporarily exist as a result of eating a meal rich in carbohydrates.  
               If the concentration of glucose is too low (below 3.8 mml/l), a condition of 
hypoglycemia exists. Hypoglycemia is characterized by general weakness, trembling, 
drowsiness, headache, profuse perspiration, rapid heartbeat, and possible loss of 
consciousness. These definitions are illustrated in Figure 2.2. 
 
 
Figure 2.1. The extraction of energy from  food . In the first stage large molecule in food 
broken down  into smaller units, in stage two the small units are degraded to a few simple units 
that play a role in metabolism  and the third  stage consists of the citric acid and oxidative  
phosphorylation (Stryer and Jeremy, 2007). 
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2.2.3.  Insulin 
From section 2.2.2 it is noted that insulin plays an important role in the 
metabolism of glucose and any disruption to any stage of its metabolism will be reflected 
on the effectiveness of insulin in the body, which contributes to the growing symptoms of 
diabetes. To understand the disease, one needs to first understand the normal physiology 
on insulin action, which it plays important role in glucose hemostasis.  Insulin is secreted 
in response to a rise in blood glucose concentrations and stimulation of the β cells of the 
pancreas by parasympathetic nervous system. Insulin stimulated anabolic processes and 
inhibits catabolic processes.  It is the predominant hormone (along with glucagon) in the 
control of blood-glucose levels (figure 2.2). Insulin is a protein made up of  long chains (A 
and B chain)  of amino acids. The β-cells have the ability to take 86 amino acids and hook 
them together to form a long chain of amino acids called proinsulin. The active hormone 
exists as a dipeptide connected by two disulphide bond (Stryer  and Jeremy,  2007) 
After eating a meal rich in carbohydrates,  the body starts to estimate mechanism 
for the digestion and absorption of carbohydrates. Hyperglycemia occurs, when the 
glucose rises  to high levels.Then,the β cells of the pancreas secrete insulin to begin  
specific  interrelated mechanisms aim to maintain the level of glucose in the body. The 
insulin has four major actions. These include: 
 Increase the movement of glucose through membrane of adipose and muscle cells. 
 Enzyme system starts multi-reactions in the liver and muscle cells for conversion 
of glucose to glycogen. 
 Slow-down of gluconeogenesis and regulation of lipogenesis in liver and muscle 
cells. 
Stimulation of general effect by promotion of protein synthesis and growth 
((Klover and Mooner, 2004). 
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 The aim of these actions is to promote the entrance of glucose and amino acids in 
cells of muscle tissues, adipose tissue and connective tissue. Glucose enters the cell by 
facilitated diffusion along an inward gradient created by low intracellular free glucose, and 
by the availability of a specific carrier called transporter. In the presence of insulin, the rate 
of movement of glucose into the cell is greatly stimulated in a selective fashion. During 
fasting, insulin concentrations are low while the counter-regulatory hormones glucagon, 
catecholamines and growth hormone promote hepatic glycogenlysis and gluconeogenesis 
from lactate, amino acids and glycerol (hydrolysis of triglyceride). 
   Metabolic actions of insulin result from its interaction with the insulin receptor 
(IR) found in all insulin responsive target cells (liver, muscle and adipose tissue). As 
shown in Figure 1.3 insulin binds to the α-subunit of insulin receptor (IR) and activates the 
intrinsic tyrosine kinase activity of the β-subunit of the receptor. Activated IR results in the 
subsequent phosphorylation of intracellular substrates including insulin receptor substrates 
(IRSs) such as IRS-1 and -2, phosphatidylinositol (PI) 3-kinase, and protein kinase B 
(PKB). Normal insulin action leads to increased glycogen synthesis, glucose transport, and 
lipogenesis, and decreased gluconeogenesis, glycogenolysis, and lipolysis (Klover and 
Mooner, 2004). 
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Figure 2.2.   Hormonal control  of glucose  metabolism. When glucose level  shows elevation 
(after a meal of rich carbohydrates), the insulin promotes the  glucose metabolism. Glucagon 
promotes the glucose metabolism when reduction of glucose level occurs (Cheng and Fantus, 
2005). 
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 Figure 2.3. Insulin binding  and activation of GLUT4 . The binding  of insulin to insulin receptor  
stimulate  the release of glucose which leads  to glucose utilization in the cell (Klover and Mooner, 
2004).  
 
Glucose transporter type 4 (GLUT4) is a glucose transport protein found in fat and 
striated muscle cells.  When a person with normal glucose metabolism ate the meal rich 
carbohydrates, insulin is secreted from the pancreas. Insulin starts to send signals to fat and 
muscles cells to absorb glucose from the blood by specific mechanism. Insulin invokes 
these cells to allow the insulin receptor binds on the surface of fat and muscle cells. 
Binding the insulin receptor will induce the GLUT4 protein to move from reserves held 
inside cells; GLUT4 can also be recruited to the cell surface through muscle contraction. 
In the absence of insulin or muscle contraction, GLUT4 is stored in vesicles within the 
cell. When GLUT4 is at the cell surface, glucose is transported into the cell down its 
concentration gradient. This process is called facilitated diffusion, which is very important 
in glucose metabolism because it create another process called phosphorylation. In this 
process, a phosphate group is then immediately added to the glucose by the enzyme 
hexokinase producing glucose-6-phosphate. These molecules can be used as an energy 
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source when it is metabolized through glycolysis and the Krebs cycle to produce energy 
units such as ATP and FADH. 
Defects in GLUT4 activity have been implicated in some forms of insulin 
resistance or pre-diabetes type II. Insulin resistance is a condition where the pancreas 
secretes insulin, but fat, and muscle cells do not respond to it in taking up glucose. The 
pancreas compensates by secreting extra insulin to help cells take up glucose, and insulin-
resistant patients often have high levels of glucose as well as a high blood insulin 
concentration. The pancreas eventually fails to keep up with the body's need for insulin, 
resulting diabetes type II.  
2.3.  Pathophysiological  of diabetes mellitus type II 
Diabetes mellitus type II is a complex metabolic disorder resulting from  excessive 
hepatic glucose production, decreased pancreatic insulin secretion and  insulin resistance 
in target tissues, mainly muscle and the liver (Ahmed and Goldstein., 2006). Diabetes 
mellitus type II is believed to be caused by both genetic and environmental   factors. The 
most important risk factors for diabetes mellitus type II are  believed to be obesity and 
oxidative stress. Initially, insulin resistance is compensated for, by increased insulin 
secretion by pancreatic β cell, but with time, these become exhausted and diabetes type II 
results (Cheng and Fantus, 2005). The pathogenesis of type II is summarized in figure 2.4.   
Initially, in the face of insulin resistance, compensatory increases in pancreatic insulin 
secretion are able to maintain normal glucose concentrations. However, as the disease 
progresses, insulin production gradually diminish, leading to progressive stages of 
hyperglycemia. Hyperglycemia is first exhibited in the postprandial state, since uptake by 
skeletal muscle is the metabolic fate of the majority of ingested carbohydrate energy, and 
then during fasting. As insulin secretion decreases, hepatic glucose production, normally 
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attenuated by insulin, increases. This increase is primarily responsible for the elevation of 
fasting glucose levels in patients with diabetes mellitus type II. 
Elevation of blood glucose levels are thought to occur via a number of pathways, 
primarily via deleterious effects on pancreatic ß cell function, which together with insulin 
resistance is thought to play a critical role in the pathogenesis of type II diabetes. The 
adverse effects of hyperglycemia on ß cell dysfunction can be divided into three distinct 
phenomena: glucose desensitization, ß cell exhaustion, and glucose toxicity (Kilpatric and 
Robertson, 1998). Glucose desensitization is a physiological adaptation in which the 
pancreatic ß-cell becomes rapidly yet reversibly refractory to a short exposure of elevated 
glucose. ß-Cell exhaustion is the reversible depletion of the pool of intracellular insulin 
following long-term exposure to elevated glucose. It is thought that the ß-cell defects 
associated with these two phenomena are initially reversible but that they eventually 
become irreversible following prolonged exposure to elevated glucose, a process that is 
termed glucose toxicity. One mechanism by which the effects of glucose toxicity are 
thought to be mediated is oxidative stress, a term used to describe imbalance between 
levels of free radicals and antioxidants, so hyperglycaemia is known to be one of the main 
causes of oxidative stress in patients with type II diabetes (Robertson et al, 2004).  
 
2.4.  Complications of diabetes mellitus   
 Diabetic retinopathy  
This is very common complication of diabetes mellitus which affects the retina 
and more commonly affect type I patients. Two types are common, the 
nonproliferative type where the blood vessels are closed off or weaken in the eye 
and this leads to blurred vision without blindness. The proliferative type causes a 
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proliferation or spouting of blood vessels in the retina which may lead to severe 
eye problem which may be resulted in cataract formation (Touchette, 2005).  
 Diabetic nephropathy :  
 The main changes in kidney of the diabetic occur within the glomerulus where 
cellular changes lead to a decrease in the surface area available to filter the blood 
and, consequently, a decrease in the glomerular filtration rate (GFR). In the people 
with this condition, the nephrons are unable to filter out impurities in the blood, 
and these begin to leak and impurities that supposed to be removed from the body 
end up re-circulating in the blood (Touchette, 2005). 
 Diabetic neuropathy   
While diabetes mellitus doesn’t impair the brain or spinal cord, it does effect the 
peripheral nerves in the rest of the body.This may be led to signal transduction 
errors, which are interpreted aberrantly (as pain in hands and feet ulceration, 
edema). Charcot arthropathy or muscle wastage (thigh, calf, trunk and hands),  
loss of autonomic function (postural hypotension, foot ulcers,and abnormal 
sweating), and marked weight loss (Williams and Pickup., 1999) 
 Cardiovascular  diseases 
Diabetes medication may cause certain chemical change in some of the substances 
found in the blood and this may lead to blood vessels narrowing or clogging up 
completely, resulting in a condition known as atherosclerosis. Hypertension is also 
a contributor of cardiovascular associated with diabetes mellitus (Touchette, 2005) 
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Figure 2.4. Progressive pathogenesis of type II diabetes mellitus (DeFronzo, 2004) 
NIDDM = Non–insulin-dependent diabetes mellitus, 
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2.5. Treatment and management of type II diabetes mellitus  
The goal of diabetes management is to keep blood-glucose hemostat as close to 
normal as safely possible. Since diabetes may be caused to risk for critical complications 
such as diabetes retinopathy, diabetes nephropathy and diabetes neuropathy measures to 
control blood pressure and cholesterol levels are an essential part of diabetes treatment as 
well. People with diabetes must take responsibility for their day to day care. Currently, 
diabetes type II is controlled and managed by a combination of diet restriction, weight 
reduction programs and oral hypoglycemic drugs (Day and Bailey, 2006; Evans and 
Rushakoff, 2007). Orally administered hypoglycemic agents (e.g. sulfonylureas, repaglinide, 
metformin, α-glucosidase inhibitors, thiazolidinediones (TZD) and dipeptidyl peptidase IV 
(DPP-IV) are used first (either alone or in combinations of different classes) together with 
dietary restriction and exercise programs (Day and Bailey, 2006). When hyperglycemia 
becomes severe, patients are usually switched to insulin injections.  However, current anti-
diabetic medications have toxic side effects, including, but not limited to, nausea, diarrhea,  
hypoglycemia, inflammation of the nasal passages and throat, upper respiratory tract 
infections, urinary tract infection, headache,  liver problems, lactic acidosis and weight 
gain (Bastaki, 2005;  Evanst al., 2007).  Despite the intensive use of current anti-diabetic 
agents . Nathan (1993) reported that many (more than 50%)  diabetic patients still exhibit 
poor glycemic control and some (18%) develop serious complications within six years of 
diagnosis.  This study shows the need for seeking  of new  active antidiabetic  agents  from 
other sources.  Figure 2.5 shows the summary of management of diabetes mellitus type II. 
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2.6. Mechanism of action of conventional oral hypoglycaemic drugs 
Oral hypoglycemia agents exert their glucose lowering effects via a variety of 
mechanisms (Figure 2.6). These mechanisms of action include: reduction of hepatic glucose 
production, (e.g. metformin, a biguanide), enhancement of insulin secretion by pancreatic 
beta cells, (insulin secretagoges) improvement of insulin sensitivity (e.g. TZDs and 
metformin) and inhibition of intestinal glucose digestion and absorption (α glucosidase 
inhibitors). The use of these drugs is however, limited by the fact that they have adverse side 
effects, such as potential hypoglycaemia (e.g. sulfonylurea), weight gain, (e.g. meglitinides, 
sulfonylurea and thiazolidinesdiones), gastro-intestinal discomforts (α-glucosidase inhibitors 
and α-amylase inhibitors) and lactoacidosis (metformin) (Cheng and Fantus, 2005).  
 
2.6.1. Oral antidiabetic  agents   
Five categories of oral antidiabetic agents are available namely; insulin 
scretagogues , biguanides , thiazolidinediones ,  α- glucosidase inhibitors and dipeptidyl 
peptidase IV (DPP- IV) inhibitors  
 
2.6.1.1.  Insulin  secretagogues : sulfonylureas  
Sulfonylurea (SU) drugs have been available in the United States since 1954. 
Second-generation SUs (glyburide, glipizide, and glimepiride) are more potent and 
probably safer than first-generation SUs (chlorpropamide, tolbutamide, acetohexamide, 
and tolazamide) but essentially of equal efficacy. The SUs bind to the SU receptor, found 
on the surface of pancreatic beta cells. This interaction leads to a closure of voltage-
dependent potassium adenosinetriphosphate (KATP) channels, facilitating cell membrane 
depolarization, calcium entry into the cell, and insulin secretion. Thus, SUs allow for 
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insulin release at lower glucose thresholds than normal. The main side effects of 
sulfonylureas are weight gain. Given that these drugs directly stimulate insulin secretion 
from pancreatic β-cells irrespective of plasma glucose levels, the risk of hypoglycemia is 
associated with all sulfonylureas (Cheng and Fantus, 2005). 
 
2.6.1.2. Biguanides 
Biguanides (e.g: Metformin) are a relative old antidiabetic drug that improves the 
peripheral insulin effect at the musculature  and inhibits gluconeogenesis by enhancing the 
take of glucose into the peripheral cells . The most side effects of metformin are hepatic 
impairment , renal impairment, congestive heart  failure, metabolic  acidosis  and  
dehydration (Silvio and Inzucchi, 2002). 
 
2.6.1.3. Insulin sensitizers  (thiazolidinediones) 
The thiazolidinediones (TZD) currently are available in many forms: 
Rosiglitazone, Pioglitazoneand and Troglitazone. Troglitazon was introduced in the 
United States.and it was later removed from the market because of rare idiosyncratic 
hepatocellular injury (Murphy et al, 2000). The most prominent effect of TZDs is 
increased insulin-stimulated glucose uptake by skeletal muscle cells. Thus, these agents 
decrease insulin resistance in peripheral tissues, then hepatic glucose production is 
decreased. Thiazolidinediones enhance the responsiveness and efficiency of beta cells, 
presumably by decreasing glucose and free fatty acid levels, both of which have 
deleterious effects on insulin secretion. (Silvio and Inzucchi,  2002). The major side effects 
of rosiglitazone and pioglitazone are weight gain, edema, anemia, pulmonary edema and 
congestive heart failure.  
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2.6.1.4.  α-Glucosidase inhibitors 
Acarbose is a novel antidiabetic drug that attenuates postprandial hyperglycaemia 
by delaying carbohydrates digestion. Acarbose exerts its inhibitory effects on the 
glucosidases, a family of membrane bound enzymes in the intestine that are involved in 
the digestion and uptake carbohydrate into the blood. Acarbose initiates a cascade of 
events which leads improved metabolic control in type II diabetes mellitus, by stimulating 
both the synthesis and secretion of insulin and in addition improves glycemic control 
when administrated concurrently with other antidiabetic agents. The main side effects of 
α-glucosidase inhibitors are on gastrointestinal tract. Specifically, bloating, abdominal 
discomfort, diarrhea and flatulence occur in about 20% of patients. Also α-glucosidase 
inhibitors are contraindicated in patients with irritable bowel syndrome or severe kidney or 
liver dysfunction. Inflammatory bowel disease is a relative contraindication (Hanefeld, 
1998). 
 
2.6.1.5. Dipeptidyl peptidase IV (DPP- IV) inhibitors 
Treatment of diabetic patients with drugs from the incretin family is one of the 
basic and central treatment tools available to the clinician today. The ﬁrst dipeptidyl 
peptidase IV (DPP-IV) inhibitor, Sitagliptin (brand name Januvia) and saxagliptin 
(Onglyza) were approved by the US Drug Administration in 2006 and 2007 respectively 
as treatment for diabetes concurrently with lifestyle changes (Karagiannis et al, 2012). The 
hormone glucagon-like peptide-1 or GLP-1 plays an important role in glucose 
homeostasis in the body. It has a profound action on both enhancing the pancreas cells to 
stimulate the insulin and delaying stomach emptying.Unfortunately, it is active only for a 
very short time because it is broken down by an enzyme called dipeptidyl peptidase-4, or 
DPP-IVinhibitor. The main function of the DPP-IV such as stagliptin and saxagliptin is 
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based on inhibition the enzyme activity which causes  prolonging the effect of GLP-1, and 
hence enhances insulin secretion and the slowed emptying of the stomach. Most of the 
diabetic patients have impaired GLP-1 secretion and elevated DPP-4 activity. Since DPP-
4 inhibitors enhance the body’s own ability to release insulin, they can only be used in the 
treatment of diabetes type II. As the synthetic drugs, the DPP-IV inhibitors  have side 
effects may be  appeared in the diabetic patient.such as inflammation of the nasal passages 
and throat, upper respiratory tract infections, urinary tract infection and headache 
(Karagiannis et al, 2012). 
 
2.7.  Hypoglycemic  studies  
According to the American Association for Diabetes, two tests either the fasting 
blood glucose or the glucose tolerance  test  (GTT) should be done at different times in 
order to diagnose diabetes mellitus. The glucose tolerance test, GTT, was designed 
originally to determine the tolerance for the glucose. "Tolerance" refers to the body's 
ability to handle (tolerate) glucose. However, the test is not that simple. The outcome of 
the test depends on a number of factors, including the ability of the intestine to absorb 
glucose, the capacity of the liver to take up and store glucose, the capacity of the pancreas 
to produce insulin, the amount of "active" insulin it produces, and the sensitivity of the 
cells in the body to the action of insulin. For the test, the subject fasts overnight and is then 
given a specific amount (100 grams) of glucose by mouth, during 2 hours, the glucose 
level return to below normal. Since the dose of glucose is taken by mouth, the test is called 
oral glucose tolerance test or sometimes the glucose is given subcutaneously and called 
subcutaneous glucose tolerance test (SGTT). 
In diabetic patient, fasting blood-glucose level may rises above 6.2 mmol/l-7.8 
mmol/l and falls back to control values only after 4-6 hours later or fail to fall to  normal 
